HomeCompareAULRF vs PFE

AULRF vs PFE: Dividend Comparison 2026

AULRF yields 0.06% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $31.4K in total portfolio value· pulled ahead in Year 8
10 years
AULRF
AULRF
● Live price
0.06%
Share price
$113.64
Annual div
$0.07
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.7K
Annual income
$0.01
Full AULRF calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — AULRF vs PFE

📍 PFE pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAULRFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AULRF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AULRF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AULRF
Annual income on $10K today (after 15% tax)
$4.92/yr
After 10yr DRIP, annual income (after tax)
$0.01/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, PFE beats the other by $23,128.95/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AULRF + PFE for your $10,000?

AULRF: 50%PFE: 50%
100% PFE50/50100% AULRF
Portfolio after 10yr
$35.4K
Annual income
$13,605.27/yr
Blended yield
38.45%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

AULRF
No analyst data
Altman Z
1.6
Piotroski
8/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AULRF buys
0
PFE buys
0
No recent congressional trades found for AULRF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAULRFPFE
Forward yield0.06%6.20%
Annual dividend / share$0.07$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$19.7K$51.1K
Annual income after 10y$0.01$27,210.54
Total dividends collected$6.00$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AULRF vs PFE ($10,000, DRIP)

YearAULRF PortfolioAULRF Income/yrPFE PortfolioPFE Income/yrGap
1$10,703$2.90$9,161$701.38+$1.5KAULRF
2$11,454$1.45$8,610$859.79+$2.8KAULRF
3$12,256$0.72$8,366$1,081.25+$3.9KAULRF
4$13,114$0.36$8,483$1,405.66+$4.6KAULRF
5$14,032$0.18$9,084$1,907.24+$4.9KAULRF
6$15,015$0.09$10,418$2,732.78+$4.6KAULRF
7$16,066$0.05$13,007$4,193.56+$3.1KAULRF
8← crossover$17,191$0.02$18,010$7,005.87$819.00PFE
9$18,394$0.01$28,216$12,979.89$9.8KPFE
10$19,682$0.01$51,081$27,210.54$31.4KPFE

AULRF vs PFE: Complete Analysis 2026

AULRFStock

AURELIUS Equity Opportunities SE & Co. KGaA is a private equity firm specializing in acquisitions, growth, complex transaction structures/carve outs, add on acquisitions, redemption of existing creditors, management buyouts, management buy-ins, P2Ps, industry consolidation, strategic acquisitions in special target industries for existing platform investments in lower middle market companies. The firm acquires, restructures and eventually sells companies in special situations including corporate spin-offs, corporate carve-outs, platform build-up succession issues, and privately held companies with issues. It seeks to invest in company spin-offs and medium-sized companies with unresolved succession, significant operational problems, and balance sheet problems due to high debt levels. The firm considers investments in private and public companies, which are primarily operating in industrial enterprises, Industrials & chemicals, information technology, business services, lifestyle, consumer goods, food and beverage, and telecoms, media, and technology (TMT). It seeks to invest in companies headquartered in Europe with the focus on European Developed Markets & Nordic region. The firm typically invests up to €250 million ($278.97 million) and between €5 ($5.6 million) and €80 million ($89.27 million) per deal in companies with sales between €30 million ($33.5 million) and €750 million ($838.54 million) and EBITDA margin from negative to more than 15 percent. In the UK, the firm invests up to £70 million ($93.5 million) in businesses with revenues between £30 million ($34.99 million) and £1000 million ($1331.14 million). It seeks to acquire majority stake, preferably 100 percent stake in underperforming businesses with development potential. The firm prefers to invest in equity. It seeks to exit its investments through sale to private, institutional or industrial investors or through an IPO. AURELIUS Equity Opportunities SE & Co. KGaA was founded on March 20, 2006, and is based in Grünwald, Germany with additional offices in Amsterdam, Netherlands; London, United Kingdom; Madrid, Spain; Milan, Italy; Munich; Germany; Stockholm, Sweden and Dusseldorf, North Rhine-Westphalia.

Full AULRF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this AULRF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AULRF vs SCHDAULRF vs JEPIAULRF vs OAULRF vs KOAULRF vs MAINAULRF vs JNJAULRF vs MRKAULRF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.